Oslo, Norway, 1 July 2020: Photocure ASA (OSE:PHO), today announced the
appointment of Susanne Strauss as Vice President and General Manager of Europe,
effective 1 July 2020.

[image]

"I am pleased to welcome Susanne Strauss to the Photocure team and I am
confident that Susanne's background and experience will lend itself to the
success launch of our European-wide organization this fall. Susanne will report
directly to me in her role and will be a member of Photocure's leadership team.
In addition, as part of building the larger European organization, we will
integrate our current Nordic operation led by Kristin Nyberg under Susanne's
leadership," says Dan Schneider, President and Chief Executive Officer of
Photocure.

Ms. Strauss brings over 20 years of international leadership experience in
medical devices, life sciences and pharma, living and working across Europe and
Asia with occasional remits in the U.S. Most recently Ms. Strauss held the
position of General Manager of Asia Pacific for legacy BTG at Boston Scientific
based in Hong Kong after leading BTG's Interventional Pulmonology Business as VP
Commercial and expanding BTG's Interventional Oncology Business into Europe.
Before that she worked in leadership positions for companies such as Convatec,
Janssen-Cilag and Baxter. She holds a PhD in Technical Chemistry and an MBA from
SDA Bocconi.

The appointment follows the agreement to regain the Hexvix[®] sales, marketing
and distribution rights in Europe and other markets currently controlled by
Ipsen Pharma SAS on 1 October 2020.

"To execute on this opportunity and its global strategy, Photocure is
establishing its commercial operations in Europe, with key leads already hired
both at country level and in the global functions to support the European
organization," Schneider adds. Ms. Strauss and these key leaders will be part of
the ongoing comprehensive transition activities in collaboration with Ipsen
teams. Ms. Strauss will establish a European Headquarters, hire the European
commercial team and oversee the integration with other functions to form a
complete European organization. She will work on the development of new growth
strategies and the execution of tactics in key markets throughout Europe.

"The transition activities are on track and Photocure is in the process of
establishing a distribution and third-party logistics network. We are fully
confident that we will be operationally and commercially ready for a smooth
handover on October 1. The ongoing transition activities are being facilitated
by our deep knowledge of the disease state and our product. We intend to
leverage our expertise by applying the commercial success and strong growth in
the Nordic and the U.S. markets to the European region," Schneider concludes.



Notes to editors

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)
Hexvix[®]/Cysview[®] is a drug that is selectively taken up by tumor cells in
the bladder making them glow bright pink during Blue Light Cystoscopy (BLC[TM]).
BLCT with Hexvix[®] /Cysview[®] improves the detection of tumors and leads to
more complete resection, fewer residual tumors and better management decisions.
Cysview[®] is the tradename in the U.S. and Canada, Hexvix[®] is the tradename
in all other markets.

About Bladder Cancer
Bladder cancer ranks as the sixth most common cancer worldwide with 1 650 000
prevalent cases (5-year prevalence rate), 550 000 new cases and almost 200 000
deaths annually in 2018.[1]Approx. 75% of all bladder cancer cases occur in
men.[1] It has a high recurrence rate with an average of 61% in year one and 78%
over five years.[2] Bladder cancer has the highest lifetime treatment costs per
patient of all cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. Incidence/mortality by
population. Available at: http://globocan.iarc.fr/Pages/bar_pop_sel.aspx
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. https://www.cancer.org/cancer/bladder-cancer.html

For further information, please contact:

Photocure

Dan Schneider
President and CEO
Tel: +1-609 759-6515
Email: ds@photocure.com

Erik Dahl
CFO
Tel: +47 45055000
Email: ed@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com